WDAY insider notice: 75,053 shares for sale via Morgan Stanley
Rhea-AI Filing Summary
Workday, Inc. insider notice reports a proposed sale of 75,053 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value listed as $17,500,108.01. The shares were acquired in a private placement on 12/27/2007 and payment was in cash. The filing lists the total number of shares outstanding as 217,000,000 and an approximate sale date of 10/08/2025.
The form also discloses multiple prior Rule 10b5-1 sales by related trusts and a foundation in September and October 2025, showing individual sale amounts and gross proceeds. The signer affirms no undisclosed material adverse information and references the 10b5-1 plan representation language required by the notice.
Positive
- Proposed sale routed through a major broker (Morgan Stanley Smith Barney LLC)
- Sale paperwork includes acquisition detail showing purchase in a private placement on 12/27/2007
- Multiple prior entries are explicitly labeled as 10b5-1 sales, indicating pre-arranged plans
Negative
- Several insider sales occurred in September and October 2025, showing ongoing disposition of shares
- The filing notifies a sale with an aggregate market value of $17,500,108.01, which increases available shares for market trading
Insights
Insider intends a registered sale of $17.5M of common stock via an established broker.
The filing shows a planned brokered sale of 75,053 shares on 10/08/2025, acquired in a private placement on 12/27/2007. The transaction is being processed through Morgan Stanley Smith Barney LLC and is reported under Rule 144.
Related entries list multiple prior 10b5-1 sales in September and October 2025, indicating an active, pre‑arranged selling program. Watch for completed trade reports around the stated date to confirm execution and any short‑term effect on available float.
Filing is a routine Rule 144 notice with 10b5-1 sale history and required seller attestations.
The document discloses acquisition details, payment method, and an attestation that no undisclosed material adverse information exists. Several prior sales are explicitly labeled as 10b5-1, meeting the standard disclosure pattern for pre‑arranged insider sales.
Key compliance items to note are the plan adoption/notice dates and broker routing; confirmation filings and Form 4s should be reviewed to verify consistency with these entries within the normal reporting window.